Allspring Global Investments Holdings LLC Acquires 76,728 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Allspring Global Investments Holdings LLC grew its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 185.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 118,074 shares of the biopharmaceutical company's stock after acquiring an additional 76,728 shares during the period. Allspring Global Investments Holdings LLC owned about 0.09% of Dynavax Technologies worth $1,651,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Wakefield Asset Management LLLP bought a new position in shares of Dynavax Technologies during the fourth quarter valued at $828,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Dynavax Technologies by 7.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 87,116 shares of the biopharmaceutical company's stock worth $1,218,000 after buying an additional 6,296 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Dynavax Technologies during the fourth quarter worth $209,000. AlphaMark Advisors LLC bought a new position in Dynavax Technologies during the fourth quarter worth $230,000. Finally, Legato Capital Management LLC bought a new position in Dynavax Technologies during the fourth quarter worth $812,000. Institutional investors own 96.96% of the company's stock.

Insider Activity

In other news, CAO Justin Burgess sold 20,526 shares of Dynavax Technologies stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $12.78, for a total transaction of $262,322.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.98% of the company's stock.

Wall Street Analysts Forecast Growth

DVAX has been the subject of a number of analyst reports. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. The Goldman Sachs Group began coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They issued a "neutral" rating and a $20.00 price target for the company. Finally, StockNews.com cut shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Wednesday, April 17th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $25.00.

Dynavax Technologies Stock Performance

NASDAQ:DVAX traded down $0.08 during trading hours on Tuesday, reaching $11.76. The company had a trading volume of 1,442,812 shares, compared to its average volume of 2,042,978. The company has a current ratio of 13.81, a quick ratio of 12.96 and a debt-to-equity ratio of 0.41. The business's 50-day simple moving average is $12.31 and its two-hundred day simple moving average is $13.26. Dynavax Technologies Co. has a twelve month low of $10.06 and a twelve month high of $15.15.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.